US at a glance
- Population
- 341.8 million 2025
- Life expectancy at birth
- 78.9 years, 2024
- People aged 65 and over
- 18.4 % of people, 2025
- Health spending per person
- 13,473 US$ per person, 2023
- Doctors
- 3.68 per 1,000 people, 2022
Updated
Reviewed by Chandani Patel
US Antiemetic Drugs Market Industry Trends and Forecast to 2034: Segmented by (Drug Class, Indication, End User, Region) - Growth, Market Size, Future Prospects & Competitive Analysis, 2024-2034
Values shown here are placeholder estimates, not researched figures. Researched 2024 historical, 2025 base-year and 2026–2034 forecast values are prepared with the full report.
Source: Acuitas Health Analytics. Full methods, sources and usage terms come with report purchase.
$411.9 Mn total, 2026–2034
| Year | Market size | Change that year | Since 2025 |
|---|---|---|---|
| 2024 (estimate) | $2.47 Bn | — | — |
| 2025 (base) | $2.51 Bn | +$42.0 Mn | — |
| 2026 (forecast) | $2.56 Bn | +$42.7 Mn | +1.7% |
| 2027 (forecast) | $2.60 Bn | +$43.5 Mn | +3.4% |
| 2028 (forecast) | $2.64 Bn | +$44.2 Mn | +5.2% |
| 2029 (forecast) | $2.69 Bn | +$45.0 Mn | +7% |
| 2030 (forecast) | $2.74 Bn | +$45.7 Mn | +8.8% |
| 2031 (forecast) | $2.78 Bn | +$46.5 Mn | +10.6% |
| 2032 (forecast) | $2.83 Bn | +$47.3 Mn | +12.5% |
| 2033 (forecast) | $2.88 Bn | +$48.1 Mn | +14.4% |
| 2034 (forecast) | $2.93 Bn | +$48.9 Mn | +16.4% |
Placeholder estimates. Each year is projected from our earlier market estimate and its CAGR. Researched values come with the full report.
| Market size, 2025 | $2.51 Bn placeholder estimate |
|---|---|
| Forecast, 2034 | $2.93 Bn placeholder estimate |
| Growth (CAGR), 2025–2034 | 1.7% placeholder estimate |
| Years | 2024 historical · 2025 base year · 2026–2034 forecast |
| Segments | Drug class, indication and end user (see all) |
| Key players | Merck & Co., Inc., Helsinn, Heron Therapeutics, Novartis AG, Eisai Co. (see all) |
| Regulator in the US | FDASource: US Food and Drug Administration. Checked 14 Nov 2026. |
| Formats | PDF, PPTX, XLSX |
Sizes and growth here are placeholder estimates, not researched figures. Researched figures come with the full report.
Antiemetic drugs prevent nausea and vomiting from chemotherapy, surgery, pregnancy and motion sickness.
Key segments of the antiemetic Drugs market include drug class (5-HT3 Antagonists, NK1 Antagonists and Dopamine Antagonists) and indication (Chemotherapy-Induced, Post-Operative and Pregnancy).
More surgery and intensive care, rising infection risks, new specialty medicines and the growth of hospital pharmacy services are driving the antiemetic Drugs market.
Ready-to-use formulations, biosimilars and supply security programmes give the antiemetic Drugs market room to grow.
Drug shortages, price controls, generic competition and strict hospital budgets hold back the antiemetic Drugs market.
The antiemetic Drugs market is moderately concentrated. Leading companies compete on product innovation, clinical evidence, pricing and geographic reach, and use partnerships and acquisitions to expand their portfolios.
New drugs need approval from the US Food and Drug Administration (FDA); many over-the-counter medicines are sold under FDA monographs instead.[1] Medicare covers people aged 65 and over and some younger people with disabilities, and Medicaid covers many people on low incomes; both are run with the Centers for Medicare & Medicaid Services (CMS).[2]
[1] US Food and Drug Administration. Checked 14 Nov 2026.
[2] Centers for Medicare & Medicaid Services. Checked 14 Nov 2026.
Regulators such as the US FDA, the European Medicines Agency and national drug authorities set approval, pricing and safety rules for antiemetic Drugs. Reimbursement decisions by public payers and insurers shape how fast new therapies reach patients in US.
What doctors and scientists are doing in Antiemetic Drugs right now, from free public sources.
Sources: PubMed (US National Library of Medicine), ClinicalTrials.gov, World Bank. Fetched 12 Nov 2026. Papers and trials are found by search words, so the counts are a guide. Titles only; read each paper at its source.
[1] World Bank Open Data, Health spending per person (US$ per person). Retrieved 16 Nov 2026.
[2] World Bank Open Data, Doctors (per 1,000 people). Retrieved 17 Nov 2026.
[3] World Bank Open Data, People aged 65 and over (% of people). Retrieved 16 Nov 2026.
From our blog
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
US · 1 shared keyword
Digital Health · US
Digital Health · US
Medical Devices · US
Medical Devices · US
Digital Health · US
Healthcare Services · US